Press Release
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
28 Mar, 2022
121
3703
InnoCare Releases 2021 Annual Results and Business Highlights
23 Mar, 2022
156
3688
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China
14 Mar, 2022
108
3680
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022
11 Mar, 2022
75
3677
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
02 Mar, 2022
83
3671
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
22 Feb, 2022
113
3657
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
18 Jan, 2022
66
3650
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
07 Jan, 2022
116
3643